Clinical parameters and lung functions of the two groups
| Formoterol | Placebo | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (week 0) | Change at first visit (week 3) from baseline | Change at second visit (week 6) from baseline | Baseline (week 0) | Change at first visit (week 3) from baseline | Change at second visit (week 6) from baseline | ||
| FEV1 (% predicted) | 79 (60 to 116) | 9.5 (−6 to 30) | 3.0 (−23 to 29) | 80 (63 to 107) | 1.0 (−12 to 19) | 1.0 (−12 to 19) | |
| sGaw (% predicted) | 77.5 (53 to 150) | 3.5 (−48 to 13) | 0 (−42 to 107) | 62.5 (29 to 96) | 2.0 (−37 to 107) | 10 (−23 to 90) | |
| TLC (% predicted) | 103.5 (90 to 187) | 4.5 (−14 to 42) | 4.5 (−17 to 53) | 109 (89 to 125) | 2.5 (−34 to 88) | 5.0 (−11 to 42) | |
| RV (% predicted) | 159 (85 to 372) | 1.5 (−91 to 54) | 5.5 (−82 to 259) | 133 (73 to 304) | −0.5 (−79 to 385) | 7.5 (−5.8 to 192) | |
| FVC (% predicted) | 91 (69 to 137) | 2.5 (−33 to 35) | 1.5 (−31 to 40) | 94 (76 to 121) | 4.5 (−16 to 84) | 3.0 (−9 to 17) | |
| FRC (% predicted) | 132.5 (94 to 234) | −4 (−42 to 62) | 4.5 (−48 to 150) | 132.5 (98 to 200) | 4.5 (−32 to 186) | 6.5 (−41 to 112) | |
| PC20 (mg/ml) | 0.295 (0.04 to 1.87) | – | 0.050 (0.57 to 0.74) | 0.3 (0.08 to 2.24) | – | 0.02 (−0.5 to 0.46) | |
| mPEFR (l/min) | 239.5 (129 to 295) | 11.52-150 (−2 to 206) | 192-150(2 to 181) | 212.5 (144 to 390) | 1.0 (−24 to 50) | 0 (−35 to 43) | |
| ePEFR (l/min) | 243.5 (139 to 303) | 10.52-150 (−10 to 166) | 192-150 (−9 to 148) | 219 (145 to 390) | −1.0 (−46 to 50) | 0 (−47 to 20) | |
| vPEFR (%) | 2.75 (0 to12) | −1.1252-150(−9 to 3.33) | −1.32-150 (−12 to 2.4) | 2.0 (0 to 17) | −0.2 (−16 to 2.4) | 0 (−24 to 1.8) | |
| β2 agonist use2-151(per week) | 3.0 (2 to 6) | −22-150 (−4 to −1) | −32-150 (−6 to −2) | 3.0 (2 to 10) | −1.02-150 (−2 to 1) | 0 (−2 to 2) | |
| Asthma symptom score2-152 | 3.0 (2 to7) | −32-150 (−5 to −2) | −32-150 (−7 to −2) | 3.5 (2 to 12) | −1.02-150 (−4 to 0) | 0 (−1 to 1) | |
↵2-150 p < 0.05 compared with the corresponding baseline value (Wilcoxon test).
↵2-151 Each use consisted of two puffs of salbutamol (100 μg/puff).
↵2-152 Night time cough, daytime cough, wheezing or shortness of breath rated on a scale from 0 to 3 (maximum, 9).
ePEFR, evening peak expiratory flow rate; FEV1, forced expiratory volume in one second; FRC, functional residual capacity, FVC; forced vital capacity; mPEFR, morning peak expiratory flow rate; PC20, 20% decrease in FEV1; RV, residual volume; sGAW, specific conductance; TLC, total lung capacity; vPEFR, variability of peak expiratory flow rate.